You are here

Alison Leed


Klarin D, Zhu QM, Emdin CA, et al. Genetic analysis in UK Biobank links insulin resistance and transendothelial migration pathways to coronary artery disease. Nat Genet. 2017;49(9):1392-1397.

Clifton MC, Dranow DM, Leed A, et al. A maltose-binding protein fusion construct yields a robust crystallography platform for MCL1. PLoS One. 2015;10(4): e0125010.

Fang C, D’Souza B, Thompson CF, et al. Single diastereomer of a macrolactam core binds specifically to myeloid cell leukemia 1 (MCL1). ACS Med Chem Lett. 2014;5(12):1308-1312.

Alison Leed, Ph.D.

Alison Leed is a senior research scientist I in the biophysics group within the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. She leads a drug discovery project team as part of the Broad–Bayer collaboration for cardiovascular disease and supports the biochemistry and biophysics efforts of other CDoT teams. She has extensive experience in protein and small molecule nuclear magnetic resonance (NMR) and additional expertise in early hit-to-lead drug discovery, fragment- and structure-based drug design, and biophysical assay development.

Prior to joining the Broad Institute in 2012, Leed completed her doctoral studies and postdoctoral training at Harvard Medical School (HMS), in the laboratory of Gerhard Wagner. At HMS, she used multi-dimensional NMR to determine protein structures and study protein-protein interactions. She also served as a consultant for Eutropics Pharmaceuticals, providing experimental NMR data to support a drug-discovery program. 

Leed holds a Ph.D. in biological chemistry and molecular pharmacology from HMS and a B.S. in biochemistry, with a minor in mathematics, from Georgetown University, where she was a John Carroll Scholar.

Contact Alison Leed via email at

June 2021